SEC Form 4 · accession 0001363763-16-000023
RespireRx Pharmaceuticals Inc. · RSPI
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
James Sapirstein
Director
Period of report
Mar 31, 2016
Accepted (ET)
Apr 4, 2016 · 5:52 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000849636
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock Options (to purchase shares of Common Stock)F1 | $0.0227 | Mar 31, 2016 | A | 10,000,000 | A | — | Mar 31, 2021 | Common Stock | 10,000,000 | 10,000,000 | D |
| Common Stock Options (to purchase shares of Common Stock)F2 | $0.0197 | holding | — | — | — | — | Aug 18, 2022 | Common Stock | 3,000,000 | 3,000,000 | D |
| Common Stock Options (to purchase shares of Common Stock)F3 | $0.025 | holding | — | — | — | — | Jun 30, 2022 | Common Stock | 2,000,000 | 2,000,000 | D |
Explanation of responses
- F1These Common Stock Options vest in four equal installments: 25 percent on March 31, 2016 (the grant date), 25 percent on June 30, 2016, 25 percent on September 30, 2016, and 25 percent on December 31, 2016.
- F2These Common Stock Options vest in four equal installments: 25 percent on December 31, 2015, 25 percent on March 31, 2016, 25 percent on June 30, 2016, and 25 percent on September 30, 2016.
- F3The Common Stock Options vest in three installments: 50 percent on June 30, 2015, 25 percent on September 30, 2015, and 25 percent on December 31, 2015.